BLUE News and Press, bluebird bio Inc. From 11/22/21

bluebird bio (NASDAQ:BLUE) gains 12% premarket after the FDA accepted for priority review, the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel). The agency has set a PDUFA goal date of May 20, 2022. Beti-cel is a potentially transformative gene therapy for...

If approved, beti-cel will be the first one-time treatment option to address the underlying genetic cause of disease Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased r...

Clear Blue Technologies International (OTCQB:CBUTF): Q3 Adjusted EBITDA was -$0.33M versus -$0.80M in Q3 2020 Revenue of $2.25M (+139.4% Y/Y) Press Release For further details see: Clear Blue Technologies International reports Q3 results

Gainers: Pioneer Power Solutions (NASDAQ:PPSI) +88%. CBAK Energy Technology (NASDAQ:CBAT) +39%. Arbe (NASDAQ:ARBE) +33%. The Trade Desk (NASDAQ:TTD) +29%. Autolus (NASDAQ:AUTL) +25%. Gaucho Group (NASDAQ:VINO) +24%. Cronos (NASDAQ:CRON) +21%. Bit Brother (NASDAQ:BTB) +22%. Lightbridge (NASDAQ...

Gainers: Autolus Therapeutics AUTL +33%, PetVivo PETV +21%, Cronos (NASDAQ:CRON) +19%, Tenaya Therapeutics (NASDAQ:TNYA) +16%, Privia Health PRVA +13%. Losers: GT Biopharma (NASDAQ:GTBP) -29%, Ontrak (NASDAQ:OTRK) -19%, Molecular Partners...

Bluebird bio (BLUE -17.7%) is trading lower with double-digit losses for the second straight session as two Wall Street firms lowered their ratings on the biotech that has just announced the spinoff of its oncology business, 2seventy bio (NASDAQ:TSVT). Morgan Stanley expects challen...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to fresh record highs Friday following a stronger than expected jobs report that showed 531,000 jobs added in October and a re...

It is another forgetful day for bluebird bio (BLUE -42.7%) as the shares recorded the biggest-ever one-day decline after the gene-therapy focused biotech reported worse-than-expected financials for Q3 2021. While revenue increased ~18% YoY to $23M, the cash and equivalents, including marketab...

bluebird bio (NASDAQ:BLUE): Q3 GAAP EPS of -$3.16 misses by $0.51. Revenue of $22.7M (+17.8% Y/Y) misses by $16.37M. Press Release Cash, cash equivalents and marketable securities as of September 30, 2021, and December 31, 2020, were $970.7M and $1.27B, respectively. For further details see...

– Company separation completed on November 4, 2021 – bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021. “This quarter was about preparing for the completion of th...